124 related articles for article (PubMed ID: 37766511)
1. Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization.
Hao X; Li Y; Zhang Y; Bian J; Zhao J; Zhao Y; Hu L; Luo X; Yang C; Feng Y; Huang L
Br J Clin Pharmacol; 2024 Feb; 90(2):440-451. PubMed ID: 37766511
[TBL] [Abstract][Full Text] [Related]
2. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population.
Li Y; Zhang Y; Zhao J; Bian J; Zhao Y; Hao X; Liu B; Hu L; Liu F; Yang C; Feng Y; Huang L
J Chemother; 2024 May; 36(3):179-189. PubMed ID: 37599449
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
4. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
Gautier-Veyret E; Thiebaut-Bertrand A; Roustit M; Bolcato L; Depeisses J; Schacherer M; Schummer G; Fonrose X; Stanke-Labesque F
Br J Clin Pharmacol; 2021 Jun; 87(6):2534-2541. PubMed ID: 33217017
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
7. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
8. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
[TBL] [Abstract][Full Text] [Related]
9. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong X; Tong X; Ju Y; Du X; Li Y
Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
[TBL] [Abstract][Full Text] [Related]
11. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
[TBL] [Abstract][Full Text] [Related]
12. Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole.
Jia SJ; Gao KQ; Huang PH; Guo R; Zuo XC; Xia Q; Hu SY; Yu Z; Xie YL
Front Pharmacol; 2021; 12():666296. PubMed ID: 34113252
[No Abstract] [Full Text] [Related]
13. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
[TBL] [Abstract][Full Text] [Related]
14. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X; Zhao J; Wen T; Liao X; Luo B
Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
[TBL] [Abstract][Full Text] [Related]
16. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.
Aiuchi N; Nakagawa J; Sakuraba H; Takahata T; Kamata K; Saito N; Ueno K; Ishiyama M; Yamagata K; Kayaba H; Niioka T
Pharmacol Res Perspect; 2022 Apr; 10(2):e00935. PubMed ID: 35199485
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
[TBL] [Abstract][Full Text] [Related]
18. Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans.
Schulz J; Michelet R; Zeitlinger M; Mikus G; Kloft C
Pharm Res; 2022 Dec; 39(12):3279-3291. PubMed ID: 36271205
[TBL] [Abstract][Full Text] [Related]
19. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
